



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09%76,620	10/02/2000	Francis Lawrence Richter	163.1406US01	3125	
23552	7590 05/01/2003				
MERCHANT	Γ& GOULD PC		EXAMI	NER	
P.O. BOX 290 MINNEAPOL	3 IS, MN 55402-0903	DEL	DELACROIX MUI	CROIX MUIRHEI, CYBILLE	
			ART UNIT	PAPER NUMBER	
			1614	1>	
			DATE MAILED: 05/01/2003	1/	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	_	09/676,620	RICHTER ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Cybille Delacroix-Muirheid	1614				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with	the correspondence address				
THE - Exte after - If the - If NO - Failu - Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION.  nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period we tree to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a repl within the statutory minimum of thirty ( ill apply and will expire SIX (6) MONTH cause the application to become ABAN	y be timely filed  30) days will be considered timely. IS from the mailing date of this communication.  NDONED (35 U.S.C. § 133).				
1)⊠	Responsive to communication(s) filed on 23 L	<u> December 2002</u> .					
2a)⊠	This action is <b>FINAL</b> . 2b) ☐ Thi	is action is non-final.					
3)	<u></u>						
·	ion of Claims						
•	4) Claim(s) <u>1,6-16,19-23 and 28-39</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
·	5) Claim(s) is/are allowed.						
	S)						
	Claim(s) is/are objected to.	. ala atian aa ay iya wa ay t					
	Claim(s) are subject to restriction and/or ion Papers	election requirement.					
	The specification is objected to by the Examiner	·.					
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
Priority ι	under 35 U.S.C. §§ 119 and 120						
13)[	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)	☐ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority documents	s have been received.					
	2. Certified copies of the priority documents	s have been received in App	olication No				
* 5	<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application							
a	a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
ر رے رہ Attachmen		o priority under 00 0.0.0. g	5 120 dilu/01 121.				
1)  Notic 2)  Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Info	mmary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)				

Application/Control Number: 09/676,620 Page 2

Art Unit: 1614

### **DETAILED ACTION**

1. Claims 1, 6-16, 19-23, 28-39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Andrews 5,569,461 (already of record) and Kabara 5,208,257 (already of record) in view of Kross, WO 00/13506 (submitted by Applicant).

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

## Response to Amendment

The following is responsive to Applicant's amendment received Dec. 23, 2002.

Claims 2, 3, 5, 17, 24, 25, 27 are cancelled without prejudice or disclaimer. New claims 38 and 39 are added. Claims 1, 6-16, 19-23, 28-39 are currently pending.

The previous claims rejection under 35 USC 112, paragraph 1, set forth in paragraph 1 of the office action mailed Sep. 24, 2002 **is withdrawn** in view of Applicant's amendment and the remarks contained therein.

However, Applicant's arguments traversing the previous claims rejection under 35 USC 103(a) set forth in paragraphs 3-4 of the office action mailed Sep. 24, 2002 have been considered but are not found to be persuasive.

Said rejection is maintained essentially for the reasons given previously in the office action mailed Sep. 24, 2002 with the following additional comment:

Application/Control Number: 09/676,620

Art Unit: 1614

It is essentially Applicant's position that the prior art does not disclose an antimicrobial composition comprising an antimicrobial component consisting essentially of heptanoic acid. Applicant argues that the prior art discloses antimicrobial components that require the addition of significant active ingredients other than heptanoic acid. For example, the Andrews and Kabara references disclose antimicrobial compositions that require propylene glycol and fatty acid esters for its antimicrobial activity. None of the references, disclose that heptanoic acid is a sufficient antimicrobial agent.

Page 3

Said arguments have been considered but are not found to be persuasive.

The transitional phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps "and those that do not materially affect the basic and novel characteristic(s)" of the claimed invention. *In re Herz*, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) If an applicant contends that additional steps or materials in the prior art are excluded by the recitation of "consisting essentially of," applicant has the burden of showing that the introduction of additional steps or components would materially change the characteristics of applicant's invention. *In re De Lajarte*, 337 F.2d 870, 143 USPQ 256 (CCPA 1964). Please see MPEP 2111.03. In this case, Applicant has not clearly shown, on the record, how the additional antimicrobial ingredients of the prior art would materially change the characteristics of the claimed invention. The prior art to Kabara discloses antimicrobial compositions containing heptanoic acid, thus suggesting that heptanoic acid has antimicrobial activity. Applicant has not clearly argued how the additional antimicrobial

Application/Control Number: 09/676,620 Page 4

Art Unit: 1614

components of the prior art, which Applicant attempts to exclude, would not materially affect the antimicrobial activity of heptanoic acid and thus the overall composition.

With respect to new claims 38-39, applicant has the burden of showing that the introduction of additional steps or components would materially change the characteristics of applicant's invention. In re De Lajarte, 337 F.2d 870, 143 USPQ 256 (CCPA 1964). Since, Applicant has not argued how "consisting essentially of" serves to exclude the additional freezing depressant components in the prior art, these claims are rejected for reasons given previously in the office action mailed Sep. 24, 2002. Namely, it would have been obvious to one of ordinary skill in the art at the time the invention was made to combine additional anti-freeze polyols such as propylene glycol and glycerin, into one composition with the reasonable expectation that the additive effect of the polyols would result in an effective freeze-resistant antimicrobial composition.

It is for these reasons that the rejection stands.

# Claim Objections

Claim 39 is objected to because of the following informalities: in claim 39, line 1, before "wherein the freezing point depressant", the term "wherein" is duplications and should be deleted. Appropriate correction is required.

Application/Control Number: 09/676,620 Page 5

Art Unit: 1614

#### Conclusion

Claims 1, 6-16, 19-23, 28-39 stand rejected.

4. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cybille Delacroix-Muirheid whose telephone number is (703) 306-3227.

The examiner can normally be reached on Tue-Fri from 8:30 to 6:00. The examiner can also be reached on alternate Mondays.

Application/Control Number: 09/676,620

Page 6

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel, can be reached on (703) 308-4725. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

CDM

April 28, 2003

PRII AMER